Literature DB >> 35641438

Synthetic Reprogramming of Kinases Expands Cellular Activities of Proteins.

Veronika M Shoba1,2, Dhanushka N P Munkanatta Godage1,2, Santosh K Chaudhary1,2, Arghya Deb1,2, Sachini U Siriwardena1,2, Amit Choudhary1,2,3.   

Abstract

Phosphorylation-inducing chimeric small molecules (PHICS) can enable a kinase to act at a new cellular location or phosphorylate non-native substrates (neo-substrates)/ sites (neo-phosphorylations).[1, 2] We report a modular design and high-yielding synthesis of such PHICS that endowed multiple new activities to protein kinase C (PKC). For example, while PKC is unable to downregulate the activity of a gain-of-function variant (S180A) of Bruton's tyrosine kinase that evokes B cell malignancy phenotype, PHICS enabled PKC to induce inhibitory neo-phosphorylations on this variant. Furthermore, while PKC typically phosphorylates its membrane-associated substrates, PKC with PHICS phosphorylated multiple cytosol-based neo-substrates (e.g., BCR-ABL). Finally, a PHICS for BCR-ABL induced death of chronic myeloid leukemia cell lines. These studies show the power of synthetic chemistry to expand the chemical and functional diversity of proteins in cells using bifunctional molecules.
© 2022 Wiley-VCH GmbH.

Entities:  

Keywords:  Bifunctional Molecules; Kinase; PHICS; Phosphorylation; Protein Kinase C

Mesh:

Substances:

Year:  2022        PMID: 35641438      PMCID: PMC9527066          DOI: 10.1002/anie.202202770

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   16.823


  24 in total

Review 1.  Pick a Tag and Explore the Functions of Your Pet Protein.

Authors:  Giel Vandemoortele; Sven Eyckerman; Kris Gevaert
Journal:  Trends Biotechnol       Date:  2019-04-27       Impact factor: 19.536

Review 2.  Protein kinase C: perfectly balanced.

Authors:  Alexandra C Newton
Journal:  Crit Rev Biochem Mol Biol       Date:  2018-04       Impact factor: 8.250

Review 3.  Strategies for Engineering and Rewiring Kinase Regulation.

Authors:  James W McCormick; David Pincus; Orna Resnekov; Kimberly A Reynolds
Journal:  Trends Biochem Sci       Date:  2019-12-20       Impact factor: 13.807

4.  The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.

Authors:  John S Tokarski; John A Newitt; Chieh Ying J Chang; Janet D Cheng; Michael Wittekind; Susan E Kiefer; Kevin Kish; Francis Y F Lee; Robert Borzillerri; Louis J Lombardo; Dianlin Xie; Yaqun Zhang; Herbert E Klei
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

5.  Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.

Authors:  Adam R Johnson; Pawan Bir Kohli; Arna Katewa; Emily Gogol; Lisa D Belmont; Regina Choy; Elicia Penuel; Luciana Burton; Charles Eigenbrot; Christine Yu; Daniel F Ortwine; Krista Bowman; Yvonne Franke; Christine Tam; Alberto Estevez; Kyle Mortara; Jiansheng Wu; Hong Li; May Lin; Philippe Bergeron; James J Crawford; Wendy B Young
Journal:  ACS Chem Biol       Date:  2016-09-07       Impact factor: 5.100

6.  Dramatic switching of protein kinase C agonist/antagonist activity by modifying the 12-ester side chain of phorbol esters.

Authors:  Reiko Wada; Yutaka Suto; Motomu Kanai; Masakatsu Shibasaki
Journal:  J Am Chem Soc       Date:  2002-09-11       Impact factor: 15.419

7.  TTK/Mps1 controls nuclear targeting of c-Abl by 14-3-3-coupled phosphorylation in response to oxidative stress.

Authors:  K Nihira; N Taira; Y Miki; K Yoshida
Journal:  Oncogene       Date:  2008-09-15       Impact factor: 9.867

Review 8.  Wealth of opportunity - the C1 domain as a target for drug development.

Authors:  P M Blumberg; N Kedei; N E Lewin; D Yang; G Czifra; Y Pu; M L Peach; V E Marquez
Journal:  Curr Drug Targets       Date:  2008-08       Impact factor: 3.465

9.  Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms.

Authors:  Daniel P Duarte; Allan J Lamontanara; Giuseppina La Sala; Sukyo Jeong; Yoo-Kyoung Sohn; Alejandro Panjkovich; Sandrine Georgeon; Tim Kükenshöner; Maria J Marcaida; Florence Pojer; Marco De Vivo; Dmitri Svergun; Hak-Sung Kim; Matteo Dal Peraro; Oliver Hantschel
Journal:  Nat Commun       Date:  2020-05-08       Impact factor: 14.919

10.  Selective inhibition of BET bromodomains.

Authors:  Panagis Filippakopoulos; Jun Qi; Sarah Picaud; Yao Shen; William B Smith; Oleg Fedorov; Elizabeth M Morse; Tracey Keates; Tyler T Hickman; Ildiko Felletar; Martin Philpott; Shonagh Munro; Michael R McKeown; Yuchuan Wang; Amanda L Christie; Nathan West; Michael J Cameron; Brian Schwartz; Tom D Heightman; Nicholas La Thangue; Christopher A French; Olaf Wiest; Andrew L Kung; Stefan Knapp; James E Bradner
Journal:  Nature       Date:  2010-09-24       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.